Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with metastatic clear cell kidney cancer (a specific type of kidney cancer that has spread to other parts of the body).
- You are 18 years of age or older.
- You are well enough to carry out daily activities, either fully, with minor limitations, or with moderate limitations (confirm with trial site).
- You are currently being treated for your kidney cancer with one of two specific medications: pazopanib or cabozantinib.
- You fall into one of three kidney health groups: no kidney problems, moderate long-term kidney problems, or severe/end-stage long-term kidney problems (with or without dialysis) — the trial site will determine which group applies to you.
- You are willing and able to attend scheduled appointments, follow the study plan, and complete required tests and procedures.
- You have given your written, informed consent to take part.
- You are registered with the French Social Security system.
Who may not be able to join:
- You are taking pazopanib or cabozantinib for a reason other than clear cell kidney cancer.
- You are currently pregnant or breastfeeding.
- Regular follow-up appointments would not be possible for you due to psychological, family, social, or location-related reasons.
- You are under legal guardianship or a similar form of legal protection (confirm with trial site).
- You have taken part in another clinical trial involving a research treatment in the last 30 days before joining this study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Fanny LEENHARDT, Dr, Institut du Cancer de Montpellier (ICM)
Phone: 04 67 61 31 02
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Residual concentration at equilibrium of ITK in the blood
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.